TABLES Table 1.Cardiovascular patient-related and treatment-related risk factors (PLUS conversion in brackets) CV patient-related factors Other CV risk factors Treatment-related risk factors Smoking habit (ongoing Symptoms of congestive Doxorubicine 400 mg/mq (1+) ≤ habit or suspension year) heart failure (3+) ≤1 Blood pressure (UNL Prior cardiomyopathy (3+) Doxorubicine 400-500 mg/mq (2+) mmHg) ≤140/90 Total and HDL cholesterol Prior severe heart valvular Doxorubicine 500-600 mg/mq (2+) (UNL mg/dl) disease (3+) ≤200 Diabetes mellitus (WHO Prior mild heart valvular Doxorubicine 700 mg/mq (3+) criteria) disease (2 +) Use of any anti-hypertension Cardiovascular PLD (Caelyx) (1+) drugs (daily consumption) risk 20% (2+) ≥ Obesity (BMI Cardiovascular LED (Myocet) (1+) ≥30/kg/m2) risk 10% but <20% ≥ (1+) Age (years) Ischemic Heart disease (3+) Epirubicine < 1000 mg/mq (1+) Renal failure (1+) Epirubicine 1000 mg/mq (2+) Atrial Fibrillation (1+) Cyclophosphamide / Iphosphamide (1+) Paclitaxel (2+) Docetaxel (1+) TrasuzumAb, Lapatinib (1+) Thoracic RT (1+) < 18 aa (3+) > 60 aa (1+)
TABLES Table 1.Cardiovascular patient-related and treatment-related risk factors (PLUS conversion in brackets) CV patient-related factors Other CV risk factors Treatment-related risk factors Smoking habit (ongoing habit or suspension ≤1 year) Symptoms of congestive heart failure (3+) Doxorubicine ≤ 400 mg/mq (1+) Blood pressure (UNL ≤140/90 mmHg) Prior cardiomyopathy (3+) Doxorubicine 400-500 mg/mq (2+) Total and HDL cholesterol (UNL ≤200 mg/dl) Prior severe heart valvular disease (3+) Doxorubicine 500-600 mg/mq (2+) Diabetes mellitus (WHO criteria) Prior mild heart valvular disease (2 +) Doxorubicine 700 mg/mq (3+) Use of any anti-hypertension drugs (daily consumption) Cardiovascular risk ≥ 20% (2+) PLD (Caelyx) (1+) Obesity (BMI ≥30/kg/m2) Cardiovascular risk ≥ 10% but <20% (1+) LED (Myocet) (1+) Age (years) Ischemic Heart disease (3+) Epirubicine < 1000 mg/mq (1+) Renal failure (1+) Epirubicine 1000 mg/mq (2+) Atrial Fibrillation (1+) Cyclophosphamide / Iphosphamide (1+) Paclitaxel (2+) Docetaxel (1+) TrasuzumAb, Lapatinib (1+) Thoracic RT (1+) < 18 aa (3+) > 60 aa (1+)
2manuscriptCRCO.docx